AB
NVCT icon

Amalgamated Bank’s Nuvectis Pharma NVCT Stock Holding History

Amalgamated Bank’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-486
Closed -$4K – 2428
2025
Q4 		$4K Buy
486
+46
+10% +$300 ﹤0.01% 2802
2025
Q3 		$3K Hold
440
– – ﹤0.01% 2901
2025
Q2 		$3K Buy
+440
New +$3.99K ﹤0.01% 2925
2024
Q2 		– Sell
-231
Closed -$2K – 3080
2024
Q1 		$2K Sell
231
-739
-76% -$6.28K ﹤0.01% 2896
2023
Q4 		$8K Sell
970
-69
-7% -$615 ﹤0.01% 2897
2023
Q3 		$13K Hold
1,039
– – ﹤0.01% 2845
2023
Q2 		$17K Buy
+1,039
New +$16.6K ﹤0.01% 2814

Other funds holding NVCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Amalgamated Bank's NVCT Position: Q1 2026 in Review

Amalgamated Bank sold out of Nuvectis Pharma (NVCT) in Q1 2026, closing a stake of 486 shares — an estimated $4K sold.

Amalgamated Bank first reported a position in NVCT in Q2 2023 and held it in 7 quarters. The position peaked at $17K in Q2 2023. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Amalgamated Bank reported no remaining Nuvectis Pharma position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 486 Nuvectis Pharma shares in Q1 2026, an estimated $4K.
  • Amalgamated Bank first reported a position in Nuvectis Pharma in Q2 2023 and held it in 7 quarters.
  • Amalgamated Bank's Nuvectis Pharma position peaked at $17K in Q2 2023.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.